Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 1;7(1):40-44.
doi: 10.18683/germs.2017.1107. eCollection 2017 Mar.

Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?

Ana Belén Pérez  1 , Natalia Chueca  1 , Federico García  1
Affiliations

Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?

Ana Belén Pérez et al. Germs. .

Abstract

The need to test for resistance associated substitutions (RAS) has been intensively debated in the past two years. In the absence of pangenotypic combinations, it seems reasonable that, if available, RAS testing in the NS5A gene at baseline for genotypes 1a and 3 may help to avoid overtreatment in terms of ribavirin usage and/or prolonged treatment duration. When patients fail treatment, RAS testing may also be useful to guide the selection of the new regimen, especially for those that need urgent retreatment and that have failed a combination including an NS5A inhibitor. However, there are new drugs in the pipeline that in combination are pangenotypic, very potent and with a high genetic barrier to resistance. In this new scenario, RAS testing may not play such an important role.

Keywords: DAA; HCV; RAS; baseline; failure; new drugs.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: all authors – none to declare.

Figures

Figure 1.
Figure 1.. SVR12 rates achieved considering LDV specific RAS and a 15% cutoff. Data are presented in relation to prior interferon treatment (TN=treatment naïve; TE= treatment experienced), and cirrhosis status (C=cirrhosis; NC=non cirrhosis)
Image reproduced with permission from Elsevier (reference 3)
See this image and copyright information in PMC

References

    1. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504. - PubMed
    1. Jacobson IM, Lawitz E, Kwo PY, et al. Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Gastroenterology. 2017 Feb 10;S0016-5085(17):30150–6. pii. - PubMed
    1. Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017 Jan 17;S0168-8278(17):30011–9. pii. - PubMed
    1. AASLD/IDSA HCV Guidance Panel Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54. - PubMed
    1. European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–94. - PubMed

LinkOut - more resources